Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: A prospective cohort study

The Lancet

Volumn 380, Issue 9851, 2012, Pages 1406-1417

  Dalton, Tracy ^a   Cegielski, Peter ^a   Akksilp, Somsak ^b   Asencios, Luis ^c   Caoili, Janice Campos ^d   Cho, Sang Nae ^e   Erokhin, Vladislav V ^f   Ershova, Julia ^a   Gler, Ma Tarcela ^d   Kazennyy, Boris Y ^g   Kim, Hee Jin ^h   Kliiman, Kai ⁱ   Kurbatova, Ekaterina ^a   Kvasnovsky, Charlotte ^a   Leimane, Vaira ^j   Van Der Walt, Martie ^k   Via, Laura E ^l   Volchenkov, Grigory V ^m   Yagui, Martin A ^l   Kang, Hyungseok ⁿ  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Office of Disease Prevention and Control Region 7   (Thailand)

^c National Tuberculosis Reference Laboratory   (Peru)

^d Tropical Disease Foundation   (Philippines)

^e Yonsei University College of Medicine   (South Korea)

^f CENTRAL TUBERCULOSIS RESEARCH INSTITUTE   (Russian Federation)

^g Orel Oblast Tuberculosis Dispensary   (Russian Federation)

^h Korean Institute of Tuberculosis   (South Korea)

ⁱ TARTU UNIVERSITY HOSPITAL   (Estonia)

^j State Agency   (Latvia)

^k SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

^m Vladimir Oblast Tuberculosis Dispensary   (Russian Federation)

ⁿ National Masan Hospital   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG SCREENING; DRUG SENSITIVITY; ESTONIA; FEMALE; HUMAN; LATVIA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PERU; PHILIPPINES; POLICY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; RUSSIAN FEDERATION; SOUTH AFRICA; UNEMPLOYMENT;

EID: 84867754043     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60734-X     Document Type: Article

References (24)

1. A Wright, M Zignol, A Van Deun et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance Lancet 373 2009 1861 1873
2. WHO Multidrug and extensively drug-resistant TB (M/XDR-TB). 2010 Global Report on Surveillance and response 2010 World Health Organization Geneva
3. GLC Program applications http://www.who.int/tb/challenges/mdr/ greenlightcommittee/report-glc-applications-apr2011rev1.pdf (accessed June 1, 2012).
4. R Gupta, JP Cegielski, MA Espinal et al. Increasing transparency in partnerships for health - introducing the Green Light Committee Trop Med Int Health 7 2002 970 976
5. NS Shah, A Wright, G-H Bai et al. Worldwide emergence of extensively drug-resistant tuberculosis Emerg Infect Dis 13 2007 380 387
6. C Jeon, S Hwang, J Min et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital Clin Infect Dis 46 2008 42 49
7. WHO Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control Wkly Epidemiol Rec 81 2006 430 432
8. WHO Addressing the threat of tuberculosis caused by extensively drug-resistant Mycobacterium tuberculosis Wkly Epidemiol Rec 81 2006 386 390
9. WHO Anti-tuberculosis drug resistance in the world: fourth global report 2008 World Health Organization Geneva
10. WHO Global tuberculosis control: WHO report 2011 2011 World Health Organization Geneva
11. CLSI Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic actinomycetes: approved standard 2nd edn. 2011 Clinical Laboratory and Standards Institute Wayne, PA
12. PT Kent, GP Kubica Public health mycobacteriology: a guide for the level III laboratory 1985 US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention Atlanta, GA
13. F Post, P Wilcox, B Mathema et al. Genetic polymorphism in M tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis J Infect Dis 190 2004 99 106
14. LL Han, A Sloutsky, R Canales et al. Acquisition of drug resistance in multidrug-resistance Mycobacterium tueruclosis during directly observed empiric retreatment with standardized regimens Int J Tuberc Lung Dis 9 2005 818 821
15. JL Fleiss, B Levin, MC Paik Statistical methods for rates and proportions 3rd edn. 2003 Wiley-Interscience Hoboken, NJ
16. ME Stokes, CS Davis, GG Koch Categorical data analysis using the SAS System 2nd edn. 2009 SAS Publishing Cary, NC
17. K Kliiman, A Altraja Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Eur Respir J 33 2009 1085 1094
18. C Bonilla, A Crossa, H Jave et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible PLoS One 3 2008 e2957
19. T Prammananan, W Arjratanakool, A Chaiprasert et al. Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates Int J Tuberc Lung Dis 9 2005 216 219
20. J Andrews, NS Shah, D Weissman, A Moll, G Friedland, N Gandhi Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community PLoS One 5 2010 e15735
21. CH Liu, N Yang, Q Wang et al. Risk factors associated with fluoroquinolone-resistant tuberculosis in a Beijing tuberculosis referral hospital Respirology 16 2011 918 925
22. HT Yu, Q Wang, N Yang, HM Li, CH Liu Risk factors associated with kanamycin-resistant tuberculosis in a Beijing tuberculosis referral hospital J Med Microbiol 2012 10.1099/jmm.0.042655-0 published online March 15.
23. CN Paramasivan, F Rehman, F Wares et al. First- and second-line drug resistance patterns among previously treated tuberculosis patients in India Int J Tuberc Lung Dis 14 2010 243 246
24. P James, R Gupta, DJ Christopher, B Thankagunam, B Veeraraghavan MDR- and XDR-TB among suspected drug-resistant TB patients in a tertiary care hospital in India Clin Respir J 5 2011 19 25